GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » 3-Year ROIIC %

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) 3-Year ROIIC % : 4.78% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 4.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % or its related term are showing as below:

SHSE:688266's 3-Year ROIIC % is ranked better than
61.37% of 1416 companies
in the Biotechnology industry
Industry Median: -13.26 vs SHSE:688266: 4.78

Suzhou Zelgen Biopharmaceuticals Co 3-Year ROIIC % Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co 3-Year ROIIC % Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial -184.11 -87.09 -20.32 -9.51 4.78

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.78 -

Competitive Comparison of Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC %

For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % falls into.



Suzhou Zelgen Biopharmaceuticals Co 3-Year ROIIC % Calculation

Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -321.4214828 (Dec. 2023) - -364.9102912 (Dec. 2020) )/( 1235.917 (Dec. 2023) - 325.652 (Dec. 2020) )
=43.4888084/910.265
=4.78%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Suzhou Zelgen Biopharmaceuticals Co 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Wu Li Qing Core technical personnel
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines